Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Eton Pharmaceuticals (ETON) Invested Capital: 2019-2025

Historic Invested Capital for Eton Pharmaceuticals (ETON) over the last 7 years, with Sep 2025 value amounting to $25.9 million.

  • Eton Pharmaceuticals' Invested Capital rose 28.83% to $25.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.9 million, marking a year-over-year increase of 28.83%. This contributed to the annual value of $54.2 million for FY2024, which is 160.05% up from last year.
  • Latest data reveals that Eton Pharmaceuticals reported Invested Capital of $25.9 million as of Q3 2025, which was down 3.10% from $26.7 million recorded in Q2 2025.
  • In the past 5 years, Eton Pharmaceuticals' Invested Capital ranged from a high of $54.4 million in Q1 2025 and a low of $16.3 million during Q1 2023.
  • For the 3-year period, Eton Pharmaceuticals' Invested Capital averaged around $27.2 million, with its median value being $21.1 million (2023).
  • Per our database at Business Quant, Eton Pharmaceuticals' Invested Capital dropped by 29.97% in 2022 and then spiked by 165.39% in 2025.
  • Over the past 5 years, Eton Pharmaceuticals' Invested Capital (Quarterly) stood at $22.9 million in 2021, then fell by 19.35% to $18.5 million in 2022, then rose by 12.97% to $20.9 million in 2023, then surged by 160.05% to $54.2 million in 2024, then increased by 28.83% to $25.9 million in 2025.
  • Its Invested Capital was $25.9 million in Q3 2025, compared to $26.7 million in Q2 2025 and $54.4 million in Q1 2025.